Drugs / APC8015F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00849290 | Apr 2004 → Jan 2009 | metastatic prostate carcinoma | Dendreon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APC8015F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849290 ↗ |
| Known as | PA2024 | “AN OPEN LABEL, SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024 (APC8015F) FOR MEN WITH OBJECTIVE DISEASE PROGRESSION ON PROTOCOL...” NCT00849290 ↗ |
| Modality | Cell therapy | “APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer.” NCT00849290 ↗ |